We observed a total of 983 (1.0%) incident AF events during the follow-up period, with 124 (0.8%) and 849 (1.1%) incident AF events occurring in the SGLT2 inhibitor and DPP4 inhibitor users, respectively. This evidence concerns the gene DPP4 and atrial fibrillation.